0000905718-21-000824.txt : 20210624 0000905718-21-000824.hdr.sgml : 20210624 20210624173754 ACCESSION NUMBER: 0000905718-21-000824 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210619 FILED AS OF DATE: 20210624 DATE AS OF CHANGE: 20210624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CONRAD HERBERT J CENTRAL INDEX KEY: 0001218815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38022 FILM NUMBER: 211043906 MAIL ADDRESS: STREET 1: C/O ARBUTUS BIOPHARMA CORP. STREET 2: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Matinas BioPharma Holdings, Inc. CENTRAL INDEX KEY: 0001582554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463011414 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 908-484-8805 MAIL ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 matinasbio_fm4jun192021.xml X0306 4 2021-06-19 0 0001582554 Matinas BioPharma Holdings, Inc. MTNB 0001218815 CONRAD HERBERT J C/O MATINAS BIOPHARMA HOLDINGS, INC.. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 1 0 0 0 Common Stock, par value $0.0001 per share 2021-06-19 5 J 0 E 40000 0 A 1360905 I By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Common Stock, par value $0.0001 per share 2021-06-19 5 C 0 E 200000 0 A 1560905 I By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Common Stock, par value $0.0001 per share 2639039 I By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT) Common Stock, par value $0.0001 per share 494622 D Series B Preferred Stock 0.5 2021-06-19 5 C 0 E 100 0 D 2018-06-21 Common Stock 200000 0 I By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock. On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. /s/ Keith A. Kucinski, attorney-in fact for Herbert J. Conrad 2021-06-24